MassMutual Private Wealth & Trust FSB Purchases 8,191 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

MassMutual Private Wealth & Trust FSB grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 42.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,270 shares of the medical equipment provider’s stock after purchasing an additional 8,191 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Zimmer Biomet were worth $2,881,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZBH. Dunhill Financial LLC raised its position in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter worth $28,000. Bangor Savings Bank purchased a new position in Zimmer Biomet during the third quarter valued at $31,000. Brooklyn Investment Group bought a new stake in Zimmer Biomet during the third quarter valued at about $35,000. Finally, Quarry LP purchased a new stake in Zimmer Biomet in the second quarter worth about $53,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Oppenheimer decreased their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Barclays lowered their target price on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Royal Bank of Canada boosted their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $123.33.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $109.65 on Tuesday. The stock has a 50 day moving average price of $107.84 and a 200-day moving average price of $108.02. Zimmer Biomet Holdings, Inc. has a one year low of $100.67 and a one year high of $133.90. The stock has a market cap of $21.83 billion, a price-to-earnings ratio of 20.85, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.65 earnings per share. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.